Next, to assay the in vivo effects of glioma-derived IL-33, tumor cells expressing IL-33, or the nuclear localization-deficient IL-33 were implanted into the brains of SCID mice and monitored for tumor burden. Here, IL33 is linked to central nervous system cancer.